CN1033454C - 4-[(2-苯并噻唑基)甲氨基]-α-[(3，4-二氟苯氧基)甲基]-1-哌啶乙醇的制备方法 - Google Patents

4-[(2-苯并噻唑基)甲氨基]-α-[(3，4-二氟苯氧基)甲基]-1-哌啶乙醇的制备方法 Download PDF

Info

Publication number
CN1033454C
CN1033454C CN92101908A CN92101908A CN1033454C CN 1033454 C CN1033454 C CN 1033454C CN 92101908 A CN92101908 A CN 92101908A CN 92101908 A CN92101908 A CN 92101908A CN 1033454 C CN1033454 C CN 1033454C
Authority
CN
China
Prior art keywords
formula
compound
acid
inert solvent
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN92101908A
Other languages
English (en)
Chinese (zh)
Other versions
CN1064865A (zh
Inventor
R·A·施托布罗克斯
G·A·J·格罗韦尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1064865A publication Critical patent/CN1064865A/zh
Application granted granted Critical
Publication of CN1033454C publication Critical patent/CN1033454C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Paper (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
CN92101908A 1991-02-25 1992-02-12 4-[(2-苯并噻唑基)甲氨基]-α-[(3，4-二氟苯氧基)甲基]-1-哌啶乙醇的制备方法 Expired - Fee Related CN1033454C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65964591A 1991-02-25 1991-02-25
US659,645 1991-02-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN95105633A Division CN1117048A (zh) 1991-02-25 1995-05-30 苯并噻唑类化合物的中间体的制备方法
CN95105632A Division CN1043609C (zh) 1991-02-25 1995-05-30 含苯并噻唑类化合物的药物组合物的制备方法

Publications (2)

Publication Number Publication Date
CN1064865A CN1064865A (zh) 1992-09-30
CN1033454C true CN1033454C (zh) 1996-12-04

Family

ID=24646210

Family Applications (3)

Application Number Title Priority Date Filing Date
CN92101908A Expired - Fee Related CN1033454C (zh) 1991-02-25 1992-02-12 4-[(2-苯并噻唑基)甲氨基]-α-[(3，4-二氟苯氧基)甲基]-1-哌啶乙醇的制备方法
CN95105633A Pending CN1117048A (zh) 1991-02-25 1995-05-30 苯并噻唑类化合物的中间体的制备方法
CN95105632A Expired - Fee Related CN1043609C (zh) 1991-02-25 1995-05-30 含苯并噻唑类化合物的药物组合物的制备方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN95105633A Pending CN1117048A (zh) 1991-02-25 1995-05-30 苯并噻唑类化合物的中间体的制备方法
CN95105632A Expired - Fee Related CN1043609C (zh) 1991-02-25 1995-05-30 含苯并噻唑类化合物的药物组合物的制备方法

Country Status (36)

Country Link
US (2) US5434168A (enExample)
EP (2) EP0501552A1 (enExample)
JP (1) JP2825652B2 (enExample)
KR (1) KR0165901B1 (enExample)
CN (3) CN1033454C (enExample)
AT (1) ATE131478T1 (enExample)
AU (1) AU649788B2 (enExample)
BG (1) BG62332B1 (enExample)
CA (1) CA2104000A1 (enExample)
CY (1) CY1924A (enExample)
CZ (1) CZ284705B6 (enExample)
DE (1) DE69206787T2 (enExample)
DK (1) DK0573473T3 (enExample)
DZ (1) DZ1560A1 (enExample)
EE (1) EE02983B1 (enExample)
ES (1) ES2083737T3 (enExample)
FI (1) FI933719A7 (enExample)
GR (1) GR3018692T3 (enExample)
HK (1) HK172296A (enExample)
HU (2) HUT67695A (enExample)
IE (1) IE69567B1 (enExample)
IL (3) IL113837A (enExample)
LV (1) LV11689B (enExample)
MA (1) MA22447A1 (enExample)
MX (1) MX9200777A (enExample)
NO (1) NO300591B1 (enExample)
NZ (2) NZ248437A (enExample)
PL (1) PL168791B1 (enExample)
RO (1) RO112959B1 (enExample)
RU (2) RU2094434C1 (enExample)
SK (1) SK278705B6 (enExample)
TN (1) TNSN92017A1 (enExample)
TW (1) TW218016B (enExample)
WO (1) WO1992014731A1 (enExample)
ZA (1) ZA921341B (enExample)
ZW (1) ZW1992A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW1992A1 (en) * 1991-02-25 1993-09-22 Janssen Pharmaceutica Nv 4-/(2-benzotiazolyl)methylamino/-b-/(3,4-difluorephenoxy)methyl/-1-piperidine ethanol
TW282469B (enExample) * 1993-06-11 1996-08-01 Janssen Pharmaceutica Nv
CN1160348A (zh) * 1994-10-14 1997-09-24 詹森药业有限公司 口服沙贝鲁唑悬浮液
US5744484A (en) * 1994-11-24 1998-04-28 Janssen Pharmaceutica, N.V. Lubeluzole intravenous solutions
JPH10501823A (ja) * 1995-04-10 1998-02-17 バクスター、インターナショナル、インコーポレイテッド クモ膜下出血の治療における架橋ヘモグロビンの使用
AU7298296A (en) * 1995-10-25 1997-05-15 Janssen Pharmaceutica N.V. Lubeluzole n-oxide
US6025355A (en) 1997-05-19 2000-02-15 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
SK282769B6 (sk) * 1996-06-27 2002-12-03 Janssen Pharmaceutica N. V. N-[4-(Heteroarylmetyl)fenyl]heteroarylamín, spôsob jeho výroby a použitia, kompozícia na jeho báze
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
US6756389B2 (en) 1996-08-09 2004-06-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
IL135176A0 (en) * 1997-11-10 2001-05-20 Bristol Myers Squibb Co Benzothiazole derivatives and pharmaceutical compositions containing the same
GB9815785D0 (en) * 1998-07-20 1998-09-16 Cerebrus Ltd Chemical compounds
JP2002544268A (ja) * 1999-05-12 2002-12-24 ニューロサーチ、アクティーゼルスカブ イオンチャネル調節剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963732A (en) * 1973-05-30 1976-06-15 Tiberio Bruzzese Process for preparing dihydroxydiphenylmethane derivatives
GB1458392A (en) * 1973-11-09 1976-12-15 Ici Ltd Optically-active 1-aryloxy-2,3-epoxypropane derivatives
US4310658A (en) * 1980-06-18 1982-01-12 Allied Corporation Production of polyester thermally stabilized with an oxirane
CA1260474A (en) * 1984-12-03 1989-09-26 Raymond A. Stokbroekx Benzoxazol- and benzothiazolamine derivatives
US4861785A (en) * 1984-12-03 1989-08-29 Janssen Pharmaceutica N.V. Benzoxazol-and benzothiazolamine derivatives, useful as anti-anoxic agents
US4689330A (en) * 1985-04-15 1987-08-25 Janssen Pharmaceutica N.V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
US4749702A (en) * 1985-04-15 1988-06-07 Janssen Pharmaceutica N. V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
KR930005004B1 (ko) * 1985-04-15 1993-06-11 쟈안센 파아마슈우티카 엔. 부이. 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법
US4717760A (en) * 1986-07-10 1988-01-05 The Dow Chemical Company Fluorinated tris-epoxides based on triphenyl methane
JPH0643426B2 (ja) * 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
ZW1992A1 (en) * 1991-02-25 1993-09-22 Janssen Pharmaceutica Nv 4-/(2-benzotiazolyl)methylamino/-b-/(3,4-difluorephenoxy)methyl/-1-piperidine ethanol

Also Published As

Publication number Publication date
US5675027A (en) 1997-10-07
FI933719L (fi) 1993-08-24
TNSN92017A1 (fr) 1993-06-08
DE69206787T2 (de) 1996-06-05
FI933719A0 (fi) 1993-08-24
WO1992014731A1 (en) 1992-09-03
ES2083737T3 (es) 1996-04-16
CS51292A3 (en) 1992-09-16
HU211560A9 (en) 1995-12-28
HUT67695A (en) 1995-04-28
HU9302395D0 (en) 1993-11-29
IL113837A (en) 1996-05-14
EE02983B1 (et) 1997-04-15
IL113837A0 (en) 1995-08-31
ZA921341B (en) 1993-08-24
US5434168A (en) 1995-07-18
CA2104000A1 (en) 1992-08-26
LV11689B (en) 1997-08-20
CN1064865A (zh) 1992-09-30
DE69206787D1 (de) 1996-01-25
NO300591B1 (no) 1997-06-23
ZW1992A1 (en) 1993-09-22
NO933010D0 (no) 1993-08-24
RO112959B1 (ro) 1998-02-27
MX9200777A (es) 1992-08-01
AU649788B2 (en) 1994-06-02
SK278705B6 (sk) 1998-01-14
EP0501552A1 (en) 1992-09-02
CN1117048A (zh) 1996-02-21
IL100952A (en) 1995-12-31
EP0573473B1 (en) 1995-12-13
IL100952A0 (en) 1992-11-15
EP0573473A1 (en) 1993-12-15
KR0165901B1 (en) 1999-01-15
CY1924A (en) 1997-03-07
PL168791B1 (pl) 1996-04-30
NZ241592A (en) 1994-07-26
DK0573473T3 (da) 1996-01-29
JP2825652B2 (ja) 1998-11-18
RU2094434C1 (ru) 1997-10-27
FI933719A7 (fi) 1993-08-24
IE920575A1 (en) 1992-08-26
RU2106348C1 (ru) 1998-03-10
GR3018692T3 (en) 1996-04-30
LV11689A (lv) 1997-02-20
HK172296A (en) 1996-09-20
NZ248437A (en) 1994-07-26
CN1113437A (zh) 1995-12-20
NO933010L (no) 1993-08-24
AU1208592A (en) 1992-09-15
TW218016B (enExample) 1993-12-21
JPH06505012A (ja) 1994-06-09
BG98068A (bg) 1994-06-30
CN1043609C (zh) 1999-06-16
IE69567B1 (en) 1996-10-02
RU95112519A (ru) 1997-04-20
ATE131478T1 (de) 1995-12-15
DZ1560A1 (fr) 2002-02-17
MA22447A1 (fr) 1992-10-01
BG62332B1 (bg) 1999-08-31
CZ284705B6 (cs) 1999-02-17

Similar Documents

Publication Publication Date Title
CN1022566C (zh) 制备新的取代的1-哌啶亚烷基-吡啶并嘧啶酮或噻唑并嘧啶酮的方法
CN1145619C (zh) 1,4-苯并硫杂吖庚因衍生物、其制备方法、含有该化合物的药物及其用途
CN1033454C (zh) 4-[(2-苯并噻唑基)甲氨基]-α-[(3，4-二氟苯氧基)甲基]-1-哌啶乙醇的制备方法
CN1358184A (zh) 新药物
WO1997048698A1 (en) Compounds having effects on serotonin-related systems
CN1208415A (zh) 抑制血管生成的哒嗪胺
TW201326182A (zh) 六氫哌喃並［３，４－ｄ］［１，３］噻□－２－胺化合物類
CN87100563A (zh) 含n-杂环基-4-哌啶胺类的抗组胺组合物
CN1285831A (zh) 取代的噻唑烷二酮衍生物,其制备过程及其药学用途
CN1281453A (zh) 作为药物的5－[4－[2－(n－甲基－n－(2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮马来酸盐的水合物
CN1355801A (zh) 噻唑烷二酮衍生物及其作为抗糖尿病药的用途
CN101412714A (zh) 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮马来酸盐的水合物
CN1166171A (zh) N-取代的哌啶基双环苯甲酸酯衍生物
CN103694234A (zh) 二氢嘧啶衍生物的晶型
CN1144801C (zh) 玻璃状已知缓激肽拮抗剂
CN1045443C (zh) 新型嘌呤衍生物及其药学上允许的盐
CN1304929A (zh) 4－羟基－4－苯基哌啶衍生物及含此衍生物的药物
CN1171789A (zh) 6－[三唑基[3－(三氟甲基)苯基]甲基]－2－喹啉酮和喹啉硫酮
CN1458931A (zh) 噻唑烷二酮衍生物的酒石酸盐
CN106458902B (zh) 吡啶衍生物
CN1366520A (zh) 新型医药
CN1312809A (zh) N－取代的氮杂二环庚烷衍生物及其制备方法和用途
AU6923496A (en) Novel heterocyclic compounds
EP1119564B1 (fr) Derives d'aryl- 4-fluoro-4- (2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl -methanone comme agonistes du recepteur 5-ht1
CN100345846C (zh) 5－[4－[2－(n－甲基－n－(2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮的钠盐

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee